簡介:吉非替尼,Gefitinib是一種有效的表皮生長因子受體 (EGFR) 抑制劑,在 NR6wtEGFR 細胞中 IC50 值為 2-37 nM。
吉非替尼物理化學性質(zhì):
密度 |
1.3±0.1 g/cm3 |
沸點 |
586.8±50.0 °C at 760 mmHg |
熔點 |
119-1200C |
分子式 |
C22H24ClFN4O3 |
分子量 |
446.902 |
閃點 |
308.7±30.1 °C |
精確質(zhì)量 |
446.1521 |
PSA |
68.74 |
LogP |
4.11 |
蒸汽壓 |
0.0±1.6 mmHg at 25°C |
折射率 |
1.621 |
儲存條件 |
Store at RT |
吉非替尼詳細介紹:
中文名稱: |
吉非替尼 |
中文別名: |
吉非替尼;N-(3-氯-4-氟苯基)-7-甲氧基-6-(3-嗎啉-4-丙氧基)喹唑啉-4-胺;吉非替尼(易瑞沙);4-氨基-1Boc-哌啶-4-羧酸;Gefitinib 抑制劑;吉非替尼 標準品;吉非替尼Gefitinib;吉非替尼Iressa;吉非替尼靶向藥;吉非替尼粉末;吉非替尼固體狀;吉非替尼雜質(zhì);吉非替尼雜質(zhì)對照品;吉非替尼中間體;科研實驗吉非替尼;臨床實驗吉非替尼;鹽酸吉非替尼;鹽酸伊達比星;醫(yī)藥級吉非替尼;4-喹唑啉胺,N-(3-氯-4-氟苯基)-7-甲氧基-6-[3-(4-嗎啉基)丙氧基];吉非替尼 吉菲替尼;易瑞沙;N-(3-氯-4-氟苯基)-7-甲氧基-6-(3-嗎啉基丙氧基)喹唑啉-4-胺;格非替尼;吉非替尼API;GEFI錫IB;吉非替尼(標準品);吉非替尼工作對照品;吉非替尼(替尼類);易瑞沙(吉非替尼) |
英文名稱: |
Gefitinib |
英文別名: |
N-(3-Chloro-4-fluorophenyl)-7-methoxy-6-(3-morpholinopropoxy)quinazolin-4-amine;GEFITINIB;AKOS 91371;n-(3-chloro-4-fluoro-phenyl)-7-methoxy-6-(3-morpholin-4-ylpropoxy)quinazolin-4-amine;N-(3-Chloro-4-fluorophenyl)-7-methoxy-6-[3-(4-morpholinyl)propoxy]-4-quinazolinamine;ZD 1839;4-Quinazolinamine, N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(4-morpholinyl)propoxy]-;Gefitinib(TINIBS);Gefitinib (ZD1839);Gefitinib (ZD1839, Iressa?);Iressa;N-(3-chloro-4-fluorophenyl)-7-methoxy-6-(3-morpholin-4-ylpropoxy)quinazolin-4-amine; Irressat;ZD-1839;Gefinitib;Getfitnib;Gifitinib;Ji Fei Ji;Gefitinib WS;ZD1839;Gefitinib, >=99%;Gefitinib iMpurity;N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(morpholin-4-yl)propoxy]quinazolin-4-amine;4-(3'-Chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline;N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(4-morpholiny |
CAS號: |
184475-35-2 |
分子式: |
C22H24CLFN4O3 |
分子量: |
446.90 |
詳細描述 |
博飛美科商城提供的[Sigma-Aldrich]4-[(3-Chloro-4-fluorophenyl)amino]-7-methoxy-6-(3-morpholinopropoxy)quinazoline為博飛美科出品的,產(chǎn)品穩(wěn)定,定制速度快,極大地方便了廣大科研客戶的使用需求。產(chǎn)品包裝為50MG,安全運輸。 屬性: 質(zhì)量水平:100 測定:≥98% (HPLC) 形式:powder 顏色:white to beige 溶解性:DMSO: 10 mg/mL, clear 儲存溫度:room temp SMILES string:COC(C=C(N=CN=C1NC2=CC(Cl)=C(F)C=C2)C1=C3)=C3OCCCN4CCOCC4 InChI:1S/C22H24ClFN4O3/c1-29-20-13-19-16(12-21(20)31-8-2-5-28-6-9-30-10-7-28)22(26-14-25-19)27-15-3-4-18(24)17(23)11-15/h3-4,11-14H,2,5-10H2,1H3,(H,25,26,27) InChI key:XGALLCVXEZPNRQ-UHFFFAOYSA-N 應用: 吉非替尼已用于: 研究其在子宮內(nèi)膜癌治療中的有效應用 細胞增殖、細胞周期和細胞凋亡試驗 細胞活力測定和集落形成試驗 包裝: 10, 50 mg in glass bottle 生化/生理作用: 吉非替尼是一種選擇性表皮生長因子受體酪氨酸激酶 (EGFR TK) 抑制劑。吉非替尼具有抗腫瘤活性,已被批準用于治療非小細胞肺癌 (NSCLC)。 吉非替尼對 EGFR 酪氨酸激酶結(jié)構(gòu)域中 ATP(三磷酸腺苷)結(jié)合站點的親和力高于 ATP。因此,已知吉非替尼可抑制子宮內(nèi)膜癌的進展。 查詢關(guān)鍵詞:“184475-35-2,吉非替尼,Gefitinib,Sigma-Aldrich,上?,F(xiàn)貨。” |
吉非替尼參考文獻:
[1]. Pedersen MW, et al. Differential response to gefitinib of cells expressing normal EGFR and the mutant EGFRvIII. Br J Cancer. 2005 Oct 17;93(8):915-23.
[2]. Moasser MM, et al. The tyrosine kinase inhibitor ZD1839 ("Iressa") inhibits HER2-driven signaling and suppresses the growth of HER2-overexpressing tumor cells. Cancer Res. 2001 Oct 1;61(19):7184-8.
[3]. Morgillo F, et al. Synergistic effects of metformin treatment in combination with gefitinib, a selective EGFR tyrosine kinase inhibitor, in LKB1 wild-type NSCLC cell lines. Clin Cancer Res. 2013 Jul 1;19(13):3508-19.
[4]. Miyake K, et al. Epidermal growth factor receptor-tyrosine kinase inhibitor (gefitinib) augments pneumonitis, but attenuates lung fibrosis in response to radiation injury in rats. J Med Invest. 2012;59(1-2):174-85.
[5]. Noh CK, et al. Simultaneous quantification of volitinib and gefitinib in rat plasma by HPLC-MS/MS for application to a pharmacokinetic study in rats. J Sep Sci. 2017 Jul 27.
[6]. Dhar D, et al. Liver Cancer Initiation Requires p53 Inhibition by CD44-Enhanced Growth Factor Signaling. Cancer Cell. 2018 Jun 11;33(6):1061-1077.e6.